Update on 18F-Fluoroestradiol

IF 4.6 2区医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Seminars in nuclear medicine Pub Date : 2024-11-01 DOI:10.1053/j.semnuclmed.2024.09.001

Sophia R. O'Brien MD, MSEd , Christine E. Edmonds MD , Rebecca E. Ward MD , Neil K. Taunk MD, MSCTS , Austin R. Pantel MD, MSTR , David A. Mankoff MD, PhD

{"title":"Update on 18F-Fluoroestradiol","authors":"Sophia R. O'Brien MD, MSEd , Christine E. Edmonds MD , Rebecca E. Ward MD , Neil K. Taunk MD, MSCTS , Austin R. Pantel MD, MSTR , David A. Mankoff MD, PhD","doi":"10.1053/j.semnuclmed.2024.09.001","DOIUrl":null,"url":null,"abstract":"<div><div><sup>18</sup>F-16α-Fluoroestradiol (<sup>18</sup>F-FES) is a radiolabeled estrogen analogue positron emission tomography (PET) imaging agent that binds to the estrogen receptor (ER) in the nucleus of ER-expressing cells. Proof-of-concept studies of <sup>18</sup>F-FES demonstrated expected correlation between tumoral <sup>18</sup>F-FES-positivity on PET-imaging and ER+ status assessed on biopsy samples by radioligand binding and immunohistochemistry. After decades of study, <sup>18</sup>F-FES PET/CT gained clinical approval in 2016 in France and 2020 in the United States for use in patients with ER+ metastatic or recurrent breast cancer.</div><div>ER+ as assessed by <sup>18</sup>F-FES PET/CT has been shown to serve as a biomarker, identifying metastatic breast cancer patients who may respond to endocrine therapy and those who are unlikely to respond. In 2023, the Society of Nuclear Medicine and Molecular Imaging (SNMMI) published Appropriate Use Criteria for <sup>18</sup>F-FES PET/CT, identifying four indications in which use of <sup>18</sup>F-FES PET/CT was “appropriate”: (1) To assess functional ER status in metastatic lesions unfavorable to biopsy or when biopsy is nondiagnostic, (2) To detect ER status when other imaging tests are equivocal or suspicious, and at (3) initial diagnosis of metastatic disease or (4) progression of metastatic disease, for considering endocrine therapy.</div><div>This article reviews the foundations of <sup>18</sup>F-FES imaging, including normal distribution, false positives, and false negatives, and describes the most up-to-date clinical uses as well as emerging research in breast cancer and other patient populations.</div></div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":"54 6","pages":"Pages 812-826"},"PeriodicalIF":4.6000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in nuclear medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0001299824000771","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

¹⁸F-16α-Fluoroestradiol (¹⁸F-FES) is a radiolabeled estrogen analogue positron emission tomography (PET) imaging agent that binds to the estrogen receptor (ER) in the nucleus of ER-expressing cells. Proof-of-concept studies of ¹⁸F-FES demonstrated expected correlation between tumoral ¹⁸F-FES-positivity on PET-imaging and ER+ status assessed on biopsy samples by radioligand binding and immunohistochemistry. After decades of study, ¹⁸F-FES PET/CT gained clinical approval in 2016 in France and 2020 in the United States for use in patients with ER+ metastatic or recurrent breast cancer.

ER+ as assessed by ¹⁸F-FES PET/CT has been shown to serve as a biomarker, identifying metastatic breast cancer patients who may respond to endocrine therapy and those who are unlikely to respond. In 2023, the Society of Nuclear Medicine and Molecular Imaging (SNMMI) published Appropriate Use Criteria for ¹⁸F-FES PET/CT, identifying four indications in which use of ¹⁸F-FES PET/CT was “appropriate”: (1) To assess functional ER status in metastatic lesions unfavorable to biopsy or when biopsy is nondiagnostic, (2) To detect ER status when other imaging tests are equivocal or suspicious, and at (3) initial diagnosis of metastatic disease or (4) progression of metastatic disease, for considering endocrine therapy.

This article reviews the foundations of ¹⁸F-FES imaging, including normal distribution, false positives, and false negatives, and describes the most up-to-date clinical uses as well as emerging research in breast cancer and other patient populations.

查看原文本刊更多论文

18F-氟雌二醇的最新进展。

18F-16α-氟雌二醇（18F-FES）是一种放射性标记的雌激素类似物正电子发射断层扫描（PET）成像剂，能与表达雌激素的细胞核中的雌激素受体（ER）结合。18F-FES 的概念验证研究表明，PET 成像中肿瘤 18F-FES 阳性与活检样本中通过放射性配体结合和免疫组化评估的 ER+ 状态之间存在预期的相关性。经过数十年的研究，18F-FES PET/CT 于 2016 年在法国和 2020 年在美国获得临床批准，用于ER+转移性或复发性乳腺癌患者。18F-FES PET/CT 评估的ER+已被证明可作为一种生物标志物，识别可能对内分泌治疗有反应和不可能有反应的转移性乳腺癌患者。2023 年，核医学与分子成像学会（SNMMI）发布了《18F-FES PET/CT 适当使用标准》，确定了 "适当 "使用 18F-FES PET/CT 的四个适应症：(1)评估对活检不利或活检无诊断意义的转移性病灶的功能性ER状态；(2)在其他影像学检查结果不明确或可疑时检测ER状态；(3)转移性疾病的初步诊断或(4)转移性疾病的进展，以考虑内分泌治疗。本文回顾了 18F-FES 成像的基础，包括正常分布、假阳性和假阴性，并介绍了乳腺癌和其他患者群体的最新临床应用和新兴研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Seminars in nuclear medicine 医学-核医学

CiteScore

9.80

自引率

6.10%

发文量

审稿时长

14 days

期刊介绍： Seminars in Nuclear Medicine is the leading review journal in nuclear medicine. Each issue brings you expert reviews and commentary on a single topic as selected by the Editors. The journal contains extensive coverage of the field of nuclear medicine, including PET, SPECT, and other molecular imaging studies, and related imaging studies. Full-color illustrations are used throughout to highlight important findings. Seminars is included in PubMed/Medline, Thomson/ISI, and other major scientific indexes.